NDC product
INJECTION, SOLUTION, CONCENTRATE · Novartis Pharma Stein AG
NDC 17088-0378 · Novartis Pharma Stein AG
Key facts
| Product NDC | 17088-0378 |
|---|---|
| Nonproprietary name | tislelizumab-jsgr |
| Substances | TISLELIZUMAB |
| Dosage form | INJECTION, SOLUTION, CONCENTRATE |
| Labeler | Novartis Pharma Stein AG |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | DRUG FOR FURTHER PROCESSING |
| Marketing start | Mar 14, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: